医学
内科学
病态的
乳腺癌
HER2阴性
胃肠病学
肿瘤科
癌症
激素受体
新辅助治疗
转移性乳腺癌
作者
Wenjie Shi,Xinyu Wan,Jinzhi He,Ye Wang,Weiwei Zhang,Yinggang Xu,Xiaofeng Huang,Rui Chen,Lei Xu,Xiaoming Zha,Jue Wang
出处
期刊:Journal of Investigative Medicine
[BMJ]
日期:2023-01-19
卷期号:71 (4): 384-393
标识
DOI:10.1177/10815589231151232
摘要
Previous studies have observed that human epidermal growth factor receptor 2 (HER2)-low-positive patients and HER2-zero patients have different prognoses. This study was conducted to investigate whether there are differences in clinicopathological characteristics and the response to neoadjuvant systemic therapy (NST) defined as systemic treatment prior to surgery between HER2-low-positive patients and HER2-zero patients. We retrospectively analyzed the data of patients with HER2-negative breast cancer who received NST at the First Affiliated Hospital of Nanjing Medical University from 2014 to 2021. There were 238 patients with HER2-low-positive status and 198 patients with HER2-zero status. The proportion of hormone receptor (HR)-positive patients in the HER2-low-positive group was significantly higher than that in the HER2-zero group (82.8% vs 52.0%, p < 0.001). The HER2-low-positive group had more patients with low Ki67 expression (23.9% vs 16.2%, p = 0.045), higher mastectomy rate (94.5% vs 88.9%, p = 0.031), and larger pathological tumor size (21.6 vs 17.8 mm, p = 0.028) than the HER2-zero group. However, no significant differences were found in pathologic complete response (pCR) rates between the two groups. We draw a conclusion that patients with HER2-low status and HER2-zero status were not found to have different pCR rates after NST, irrespective of HR status. However, differences were observed in some clinicopathological characteristics between the two groups.
科研通智能强力驱动
Strongly Powered by AbleSci AI